Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk Patients

Novartis' Heart Drug Gets Accelerated Review in Britain for High-Risk Patients

Cholesterol-lowering inclisiran could be available in the country as early as 2021.

Britain's National Health Service (NHS) announced an agreement with pharmaceutical giant Novartis (NYSE:NVS) to help accelerate the review process for its heart drug inclisiran. The agreement would see inclisiran provided to patients who are at high risk of c… [+1481 chars]

Read full article | Read comments

0 comments

More health news